Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crofelemer in Pediatric Microvillus Inclusion Disease (Phase II, Italy)
2024-512845-18-00Phase 3Authorised
- Sponsor
- Napo Pharmaceuticals
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in microvillus inclusion disease (MVID) comparing Crofelemer with Placebo (2 arms). Planned start Aug 2024; status: authorised.
02
Drugs
crofelemer
03
Conditions
microvillus inclusion disease (MVID)
Beyond the preview
Go deeper on 2024-512845-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512845-18-00.